Site search2016
- 2016.12.9IRIR Information on the Initiation of Neoantigen (Genetic Variant Antigen) Peptide Vaccine Development（1393KB）
- 2016.11.21IRAnnouncement of the Acceptance of the Third Party Allocation of New Shares by Advanced Immunotherapy, Co., Ltd. (Acquisition of the Ownership)（623KB）
- 2016.11.11IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（184KB）
- 2016.8.15IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（178KB）
- 2016.8.9IRAnnouncement of Joint Research and Development with Kanagawa Cancer Center（145KB）
- 2016.7.25IRAnnouncement Concerning Development of Immunoassay Procedures Outsourced to GreenPeptide（125KB）
- 2016.5.13IRFinancial Results for the Fiscal Year ended March 31, 2016 [Japanese GAAP] (non-consolidated)（167KB）
- 2016.5.2IRCompletion of Patient Enrollment in Japanese Phase III Clinical Study on GreenPeptide's Lead Product Candidate ITK-1（86KB）
- 2016.2.12IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2016 [Japanese GAAP] (non-consolidated)（158KB）
- 2016.12.9IRIR Information on the Initiation of Neoantigen (Genetic Variant Antigen) Peptide Vaccine Development（1393KB）
- 2016.11.21IRAnnouncement of the Acceptance of the Third Party Allocation of New Shares by Advanced Immunotherapy, Co., Ltd. (Acquisition of the Ownership)（623KB）
- 2016.11.11IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（184KB）
- 2016.8.15IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（178KB）
- 2016.8.9IRAnnouncement of Joint Research and Development with Kanagawa Cancer Center（145KB）
- 2016.7.25IRAnnouncement Concerning Development of Immunoassay Procedures Outsourced to GreenPeptide（125KB）
- 2016.5.13IRFinancial Results for the Fiscal Year ended March 31, 2016 [Japanese GAAP] (non-consolidated)（167KB）
- 2016.5.2IRCompletion of Patient Enrollment in Japanese Phase III Clinical Study on GreenPeptide's Lead Product Candidate ITK-1（86KB）
- 2016.2.12IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2016 [Japanese GAAP] (non-consolidated)（158KB）